Pair page
Decapeptide-12 with Pal-GHK
Mechanism-tag overlap and published literature for Decapeptide-12 and Pal-GHK, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Decapeptide-12 unique
tyrosinase-inhibitor
Shared
cosmetic-peptide
Pal-GHK unique
palmitoylated-copper-peptide-analog
Quick facts
Decapeptide-12
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Pal-GHK
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2018 | Decapeptide-12 | Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting Night Cream, a novel triple-acting skin brightening product: a double-blind, placebo-controlled clinical study. J Clin Aesthet Dermatol. 2018;11(12):25-30. (Envy Medical triple-action cream containing dec… | human trial |
| 2009 | Decapeptide-12 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Pivotal split-face RCT pilot in five Fitzpatrick IV fema… PMID 19663110 | human trial |
| 2013 | Decapeptide-12 | Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermato… PMID 23839199 | human pilot |
| 2012 | Decapeptide-12 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Open-label evaluation of the full Lumixyl brightening system in mild-to-moderate facial melasma.) PMID 22527440 | human pilot |
| 2012 | Decapeptide-12 | Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12 (24-week photodamage study). J Drugs Dermatol. 2012. PMID: 22401652. (24-week open-label in photodamaged facial hyperpigmentation; subset-shift improvements in grade-4 severe… PMID 22401652 | human pilot |
| 2012 | Decapeptide-12 | Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38(7 Pt 1):971-984. PMID: 22583339. (Hantash-co-authored contemporary melasma-therapeutics review that situates decapeptide-12 within the broader depigmentin… PMID 22583339 | human study |
| 2019 | Decapeptide-12 | Hantash BM, Abu Ubeid A. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. 2019. (Extends decapeptide-12 mechanistic claims into SIRT-pathway anti-senescence in human keratinocytes — supports "brightening plus anti-aging" posi… | preclinical, in vitro |
| 2009 | Decapeptide-12 | Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. PMID: 19440221. (Foundational discovery paper — phage-display biopanning that identified decapeptide-12… PMID 19440221 | preclinical, in vitro |
| 1993 | Decapeptide-12 | Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100(6):806-811. (Classic determinant-of-pigmentation paper establishing tyrosinase as the rate-limiting enzyme o… | preclinical, in vitro |
| 2016 | Decapeptide-12 | Ochiai A, Tanaka S, Tanaka T, Taniguchi M. New tyrosinase inhibitory decapeptide: molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016;121(6):607-613. (Independent decapeptide-class tyrosinase-inhibitor work highlighting the role of tyrosine residues in t… | mechanism / discovery |
| 2012 | Decapeptide-12 | Ubeid AA, Do S, Nye C, Hantash BM. Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides. Biochim Biophys Acta. 2012;1820(10):1481-1489. (Extended structure-activity work from the Hantash group on the peptide-tyrosinase inhibitor scaffold.) | mechanism / discovery |
| 2014 | Decapeptide-12 | Ubeid AA, Hantash BM. Minireview: Peptide analogs and short sequence oligopeptides as modulators of skin pigmentation. Curr Top Med Chem. 2014;14(12):1418-1424. PMID: 24894693. (Review of tyrosinase-inhibitor oligopeptides and α-MSH analogs in cosmetic and dermatologic pigment m… PMID 24894693 | review |
| 2005 | Pal-GHK | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492182. (Found… PMID 18492182 | human trial |
| 1998 | Pal-GHK | Abdulghani AA, Sherr A, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastruct… | human pilot |
| 1988 | Pal-GHK | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3138181. (Th… PMID 3138181 | preclinical, in vitro |
| 2018 | Pal-GHK | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520; PMC6073405. (2018 gene-expression-based review using Broad… PMID 29986520 | mechanism / discovery |
| 2017 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PMID: 28241430. (Extension of GHK transcriptomic effects; rele… PMID 28241430 | mechanism / discovery |
| 2018 | Pal-GHK | Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Contemporary MDPI Cosmetics review of copper-peptide skin biology applicable to the Pal-GHK-in-situ-GHK-Cu formation hypothesis.) | review |
| 2015 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730; PMC4508379. (Comprehensive review of GHK's multi-pathway s… PMID 26236730 | review |
| 2008 | Pal-GHK | Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Foundational review of the parent tripeptide GHK, its tissue-remodeling biology, and the copper-coor… PMID 18644225 | review |
| 2005 | Pal-GHK | Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. Marcel Dekker, New York; 2005:549–563. (Classical cosmetic-dermatology chapter summarizing GHK-Cu-containing facial cream clinical data — the cream data most ofte… | review |
| 2003 | Pal-GHK | Sederma (Croda International). Matrixyl 3000 technical dossier and product information sheets. Sederma, Le Perray-en-Yvelines, France. 2003–2024. (Manufacturer's technical documentation for the Pal-GHK + Pal-GQPR combination active — the primary source for recommended use levels… | industry documentation |
| 2002 | Pal-GHK | Mas-Chamberlin C, Lintner K, Basset L, Adhoute H, Revuz J. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs excipient. Annales de Dermatologie et de Vénéréologie. 2002;129(1S):456. Proceedings, 20th World Congress of Dermatology, Paris. (E… | industry documentation |
| 2000 | Pal-GHK | Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. 2000;22(3):207-218. doi:10.1046/j.1467-2494.2000.00010.x. (Sederma researcher review of the palmitoyl-peptide lipi… | industry documentation |
Related pair pages
More research context
Frequently asked
Have Decapeptide-12 and Pal-GHK been studied together?
No co-administration studies between Decapeptide-12 and Pal-GHK are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Decapeptide-12 and Pal-GHK share?
Decapeptide-12 and Pal-GHK share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Decapeptide-12 and Pal-GHK?
Decapeptide-12: Cosmetic ingredient. Pal-GHK: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Decapeptide-12 and Pal-GHK?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Decapeptide-12 profile and the Pal-GHK profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026